Ludwig Maximilian University Of Munich
- Address
- lock Available on a paid plan
Psychiatry and Psychology – Mental Disorders
The Ludwig Maximilian University Of Munich is conducting research focused on early-to-mild dementia due to Alzheimer's disease within the broader field of Psychiatry and Psychology. Trials aim to evaluate a potential therapeutic and diagnostic role of Thiethylperazine to improve brain amyloid‑β clearance and delay cognitive decline.
- Investigating amyloid‑β clearance mechanisms
- Assessing early diagnostic biomarkers
- Exploring repurposed antipsychotic agents
- Evaluating cognitive outcomes in mild dementia
- Monitoring safety and tolerability over 12 months
A total of 6 trials involve 38 investigators, all centered at the Klinik und Poliklinik für Psychiatrie und Psychotherapie in Munich, Germany, advancing therapeutic options for patients with early Alzheimer's pathology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 22 therapeutic areas and 15 of 181 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 177 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 40 by active trials.
- 1Merck Sharp & Dohme LLC3active
lock +39 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB7trials
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ludwig Maximilian University Of Munich
lock Showing 1 of 74 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Double‑Blind Randomized Controlled Trial of Oral Cannabidiol Augmentation of Antipsychotic Therapy in First‑Episode Psychosis | University Of Oxford | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 181 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 9 | Unknown | 2018-03-06 | 2024-01-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.